Alliance for Regenerative Medicine

Alliance for Regenerative Medicine (ARM) is a leading international advocacy organization in the Health Care industry, founded in 2009. With a mission to champion the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society, ARM serves as a unifying force within the sector. Through influential exchanges on policies and practices, ARM actively engages key stakeholders to enable the development of advanced therapies and modernize healthcare systems. Representing more than 400 members across 25 countries, including biotechnology companies, research institutions, and patient organizations, ARM is committed to advancing the narrative with data and analysis. As the global voice of the sector, ARM plays a crucial role in shaping the future of medicine.

As a Venture capital analyst, I see ARM's dedicated focus on advocating for the transformative potential of regenerative medicine as a compelling investment opportunity. The organization's efforts to facilitate influential exchanges and engage key stakeholders align with the growing interest and investment in the healthcare and biotechnology sectors. Additionally, ARM's diverse membership base across 25 countries and its role as a global voice of the sector position it as a valuable player in the industry, offering potential for impact and growth.